Login / Signup

Descriptive Analysis for the Trend of Pharmacovigilance Planning in Risk Management Plans on New Drugs Approved During 2016-2019.

Mei KohamaTakahiro NonakaYoshiaki UyamaChieko Ishiguro
Published in: Therapeutic innovation & regulatory science (2022)
Notable changes in the three indicators during 2016-2019 were observed, which suggests that regulatory renovation has affected PVP in Japan.
Keyphrases
  • transcription factor
  • drug induced
  • cross sectional
  • adverse drug
  • health insurance
  • electronic health record